FULC
FULC clinical trials: Fulcrum Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Fulcrum Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
FULC on the catalyst calendar · FULC registry changes
- Primary completion Jun 4, 2026ActualPhase 2NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101Fulcrum Therapeutics · Sickle Cell DiseaseTerminatedFULCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2026ActualPhase 1NCT07431398Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell DiseaseFulcrum Therapeutics · Sickle Cell DiseaseTerminatedFULCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 20, 2026ActualPhase 1NCT05169580Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PociredirFulcrum Therapeutics · Sickle Cell DiseaseCompletedFULCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2024ActualPhase 2NCT04004000Evaluation of Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments of Losmapimod for FSHD1 With ExtensionFulcrum Therapeutics · Facioscapulohumeral Muscular Dystrophy 1TerminatedFULCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 19, 2024ActualPhase 3NCT05397470Efficacy and Safety of Losmapimod in Treating Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (REACH)Fulcrum Therapeutics · Facioscapulohumeral Muscular Dystrophy (FSHD)TerminatedFULCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 7, 2024ActualPhase 2NCT04264442Efficacy and Safety of Losmapimod in Treating Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD) With Open-Label Extension (OLE)Fulcrum Therapeutics · Facioscapulohumeral Muscular Dystrophy (FSHD)TerminatedFULCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 28, 2021ActualPhase 2NCT04003974Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)Fulcrum Therapeutics · Facioscapulohumeral Muscular Dystrophy (FSHD)CompletedFULCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 31, 2021ActualPhase 3NCT04511819Losmapimod Safety and Efficacy in COVID-19Fulcrum Therapeutics · COVID-19TerminatedFULCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2022ActualPhase 1NCT04586985Safety, Tolerability and Pharmacokinetics of FTX-6058Fulcrum Therapeutics · Healthy Adult SubjectsCompletedFULCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 5, 2021ActualPhase 1NCT05002231Relative Bioavailability and Food Effect Study of Losmapimod 15 mg TabletsFulcrum Therapeutics · Healthy Adult SubjectsCompletedFULCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner